HCA
CORT icon

Harbor Capital Advisors’s Corcept Therapeutics CORT Stock Holding History

Harbor Capital Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-102
Closed -$7K – 1372
2025
Q2 		$7K Buy
102
+1
+1% +$73 ﹤0.01% 1060
2025
Q1 		$12K Buy
+101
New +$6.15K ﹤0.01% 898

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Harbor Capital Advisors's CORT Position: Q3 2025 in Review

Harbor Capital Advisors sold out of Corcept Therapeutics (CORT) in Q3 2025, closing a stake of 102 shares — an estimated $7K sold.

Harbor Capital Advisors first reported a position in CORT in Q1 2025 and held it in 2 quarters. The position peaked at $12K in Q1 2025. 429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

  • Harbor Capital Advisors reported no remaining Corcept Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Harbor Capital Advisors sold 102 Corcept Therapeutics shares in Q3 2025, an estimated $7K.
  • Harbor Capital Advisors first reported a position in Corcept Therapeutics in Q1 2025 and held it in 2 quarters.
  • Harbor Capital Advisors's Corcept Therapeutics position peaked at $12K in Q1 2025.
  • 429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on Harbor Capital Advisors's 13F filing for Q3 2025, filed 15 Oct 2025.